- Home
- NBIX vs CELH Comparison
NBIX vs CELH Comparison
Compare NBIX & CELH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NBIX
- CELH
- Stock Information
- Founded
- NBIX 1992
- CELH 2004
- Country
- NBIX United States
- CELH United States
- Employees
- NBIX N/A
- CELH N/A
- Industry
- NBIX Biotechnology: Biological Products (No Diagnostic Substances)
- CELH Beverages (Production/Distribution)
- Sector
- NBIX Health Care
- CELH Consumer Staples
- Exchange
- NBIX Nasdaq
- CELH Nasdaq
- Market Cap
- NBIX 14.4B
- CELH 15.3B
- IPO Year
- NBIX 1996
- CELH N/A
- Fundamental
- Price
- NBIX $150.87
- CELH $41.73
- Analyst Decision
- NBIX Strong Buy
- CELH Strong Buy
- Analyst Count
- NBIX 18
- CELH 18
- Target Price
- NBIX $172.06
- CELH $62.39
- AVG Volume (30 Days)
- NBIX 1.0M
- CELH 6.5M
- Earning Date
- NBIX 10-28-2025
- CELH 11-06-2025
- Dividend Yield
- NBIX N/A
- CELH N/A
- EPS Growth
- NBIX 12.44
- CELH N/A
- EPS
- NBIX 4.19
- CELH 0.13
- Revenue
- NBIX $2,682,700,000.00
- CELH $2,125,838,000.00
- Revenue This Year
- NBIX $23.68
- CELH $85.38
- Revenue Next Year
- NBIX $18.02
- CELH $31.08
- P/E Ratio
- NBIX $35.78
- CELH $326.14
- Revenue Growth
- NBIX 19.61
- CELH 55.07
- 52 Week Low
- NBIX $84.23
- CELH $21.10
- 52 Week High
- NBIX $157.67
- CELH $66.74
- Technical
- Relative Strength Index (RSI)
- NBIX 59.16
- CELH 18.33
- Support Level
- NBIX $133.62
- CELH $56.96
- Resistance Level
- NBIX $157.67
- CELH $61.49
- Average True Range (ATR)
- NBIX 4.58
- CELH 2.70
- MACD
- NBIX 0.98
- CELH -2.24
- Stochastic Oscillator
- NBIX 67.98
- CELH 5.19
About NBIX Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.
About CELH Celsius Holdings Inc.
Celsius Holdings plays in the energy drink subsegment of the global nonalcoholic beverage market, with 95% of revenue concentrated in North America. The firm now owns three energy drink brands: Celsius, Alani Nu, and Rockstar Energy. It dedicates its efforts to product innovation and marketing while outsourcing manufacturing and packaging to third-party co-packers and distribution to PepsiCo. The firm issued convertible preferred shares following PepsiCo's investments in 2022 and 2025, giving the latter an 11% stake in Celsius.